Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults

NCT02826798 is registered in ClinicalTrials.gov with VBI Vaccines Inc. as lead sponsor.

NCT NCT02826798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02826798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults
Lead sponsor
VBI Vaccines Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 23, 2016
Completion date
August 24, 2017
Enrollment
128 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infections